← Back to all trials
Recruiting
NCT07079735
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Conditions: CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
Sex: All
Ages: 18 Years – 99 Years
Healthy volunteers: No
Phase: PHASE2, PHASE3
Enrollment: 150
Sponsor: Columbia University
Location: NYP-Weill Cornell New York New York
Summary
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Eligibility Criteria
Inclusion Criteria:
Patients who are \>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included.
Exclusion Criteria:
History of or suspected CMV disease within 6 months prior is excluded.
Source: ClinicalTrials.gov (NCT07079735). StuddyBuddy aggregates publicly available trial information.
